Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.

Trial Profile

Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2012

At a glance

  • Drugs Azithromycin; Tobramycin/dexamethasone
  • Indications Bacterial infections; Blepharitis; Blepharoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jan 2011 Actual end date (June 2010) added as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top